“We are committed to improving patient outcomes and reducing overall treatment costs.” affirms Robert Embree, CEO of EmeritusDX.
IRVINE, Calif. (PRWEB)
May 24, 2023
EmeritusDX, an up-and-coming cancer diagnostics and information company, has launched the MetaDX™ test. The test is a PCR-based assay that provides personalized treatment guidance for prostate cancer patients. It measures the AR-V7/AR-WT Ratio in the biopsied prostate tissue to predict patients’ resistance to Androgen Deprivation Therapy (ADT) early on in the treatment process.
According to Robert Embree, Chief Executive Officer of EmeritusDX, “MetaDX™ addresses an important treatment decision for patients diagnosed with prostate cancer. By launching this test, we continue our committed path of improving patient outcomes as well as reducing overall treatment costs.”
Androgen deprivation therapy is often used to treat hormone-sensitive advanced prostate cancer. However, resistance to this therapy can develop through multiple treatments. “Our goal is to alert physicians when resistance to therapy is identified in these patients so that effective alternative treatments are provided in the earliest possible phase,” stated the team.
The MetaDX™ test is now available at EmeritusDX’s laboratory in Irvine, CA. The test is performed on paraffin-embedded prostate tissue and takes 3-5 days to report out. Clients can order the test as a reflex or on demand.
About EmeritusDX
EmeritusDX is a cancer diagnostic and information company that specializes in delivering actionable clinical information. They perform testing that guides the diagnosis and treatment of cancer patients. EmeritusDX’s partners include hospitals, private pathology laboratories, biotechnology companies, academic institutions, contract research, and pharmaceutical development organizations. They prioritize the accuracy and timeliness of their test results.
For more information about the MetaDX™ test, please call 800-959-2846 or email contact@emeritusdx.com
Share this article via social media or email:
